ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Genitourinary Cancers

Genitourinary Cancers

Researchers have identified a subset of six biomarkers that together may predict the risk of more aggressive prostate cancer among African American men.

In this interview we discuss recent trials that looked at the use of upfront chemotherapy combined with androgen deprivation therapy in men with metastatic prostate cancer and how they have changed clinical practice.

The 2015 ASCO Annual Meeting delivered new practice-changing results in the area of prostate cancer.

The management of patients with localized prostate cancer has improved to meet clinical guidelines, according to a new study.

PSA-based screening for prostate cancer among men older than 50 has decreased since the 2012 USPSTF recommendations.

Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.

Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Pages

Subscribe to Genitourinary Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.